Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal As-Sidanah : Jurnal Pengabdian Masyarakat Jurnal Farmasi Sains dan Praktis
Riswana, Nabila Uswah
Unknown Affiliation
Religion Education Immunology & microbiology Languange, Linguistic, Communication & Media Medicine & Pharmacology Public Health Social Sciences Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
IMPROVING THE QUALITY OF LIFE OF DIABETES MELLITUS PATIENTS THROUGH THE USE OF HEALTH APPLICATIONS Hadning, Ingenida; Cahyaningsih, Indriastuti; Rokhman, M Rifqi; Riswana, Nabila Uswah
As-Sidanah Vol 6 No 1 (2024): APRIL
Publisher : LP2M Universitas Ibrahimy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35316/assidanah.v6i1.60-71

Abstract

The use of health applications is proven to improve the knowledge and quality of life of diabetes mellitus patients. The information on the application is useful in preventing complications due to diabetes mellitus and improving therapy adherence. This community service aims to socialize the use of health applications and discover their effect on increasing knowledge about diabetes mellitus. The method used by this community service is Participatory Action Research (PAR). The partner in this activity is the Pharmaceutical Installation of PKU Muhammadiyah Hospital Bantul. The target of the activity is the elderly group assisted by PKU Muhammadiyah Bantul Hospital. Community service activities have been carried out on Saturday, May 29, 2023, at PKU Muhammadiyah Hospital Bantul. Activities were filled with the implementation of gymnastics, recitation, counselling materials about Diabetes Mellitus and socialization of the use of health applications to improve the quality of life of diabetes mellitus patients. Activities were evaluated through pretests and post-tests and testimonials from participants and activity partners. Participants' knowledge of diabetes mellitus and understanding of health applications also increased, as seen from their pre-test and post-test scores. It can be concluded that this community service activity can increase participants' knowledge of diabetes mellitus and understanding of the use of health applications.
COST-EFFECTIVENESS ANALYSIS OF AMLODIPINE AND CANDESARTAN USE IN TYPE 2 DIABETES MELLITUS PATIENTS WITH COMORBID HYPERTENSION IN YOGYAKARTA, INDONESIA Hadning, Ingenida; Riswana, Nabila Uswah; Ardhani, Nariswari Cahya; Arini, Merita
Jurnal Farmasi Sains dan Praktis Vol 11 No 2 (May-August 2025)
Publisher : Universitas Muhammadiyah Magelang

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Type 2 diabetes mellitus, often accompanied by comorbid hypertension, necessitates expensive and prolonged treatment. Therefore, conducting a cost-effectiveness analysis is crucial to identify the most economically viable option by comparing the costs and therapeutic efficacy of amlodipine and candesartan in patients with type 2 diabetes mellitus and comorbid hypertension in Yogyakarta, Indonesia. This research aims to analyze therapy costs and effectiveness using pharmacoeconomic assessment, specifically calculating ACER (Average Cost-Effectiveness Ratio) and ICER (Incremental Cost-Effectiveness Ratio) values. The study uses a quantitative approach with retrospective data collection from patient medical records through total sampling. This research gathered data from 149 medical records. The cost-effectiveness analysis based on ACER values revealed the following: amlodipine 5 mg cost IDR 86; amlodipine 10 mg cost IDR 51; candesartan 8 mg cost IDR 571; candesartan 16 mg cost IDR 727. The ICER value of amlodipine 5 mg – candesartan 8 mg cost IDR 1,527; amlodipine 5 mg – candesartan 16 mg cost IDR 2,192; amlodipine 10 mg – candesartan 8 mg cost IDR –8454; amlodipin 10 mg – candesartan 16 mg cost IDR –5,979. The therapy is considered cost-effective when the ACER value is low, and the negative value of ICER indicates that the treatment has lower costs with greater effectiveness. So, using amlodipine 10 mg is the most cost-effective approach for reducing blood pressure in type 2 diabetes mellitus patients with comorbid hypertension in Yogyakarta, Indonesia.
Co-Authors Ardhani, Nariswari Cahya Arini, Merita Indriastuti Cahyaningsih, Indriastuti Ingenida Hadning Rokhman, M Rifqi